---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-123295"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:33:46.787213+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verastem: new chairman, president of development appointed; COO departs; RAMP 301 enrollment complete

## Summary
- John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.
- Matthew Ros, COO, departs; receives nine-month base salary continuation and pro-rated bonus under separation agreement.
- RAMP 301 Phase 3 trial in recurrent LGSOC completed additional enrollment of 29 patients; topline data expected mid-2027.
- Commercial launch of AVMAPKI FAKZYNJA CO-PACK progressing.

## SEC filing metadata
- accession: 0001104659-25-123295
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/0001104659-25-123295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/tm2533463d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-123295
- JSON: https://secwatch.observer/filing/0001104659-25-123295.json
- Plain text: https://secwatch.observer/filing/0001104659-25-123295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.